MCID: HPT015
MIFTS: 52

Hepatitis D

Categories: Liver diseases, Infectious diseases, Rare diseases, Genetic diseases, Gastrointestinal diseases, Immune diseases, Endocrine diseases

Aliases & Classifications for Hepatitis D

MalaCards integrated aliases for Hepatitis D:

Name: Hepatitis D 12 76 44 15
Hepatitis Delta 59 55
Hepatitis D Infection 73
Hepatitis D Virus 59
Delta Hepatitis 12
Hdv 59

Classifications:



External Ids:

Disease Ontology 12 DOID:2047
MeSH 44 D003699
SNOMED-CT 68 424460009 707341005
Orphanet 59 ORPHA402823
ICD10 via Orphanet 34 B17.0
UMLS via Orphanet 74 C0011226
UMLS 73 C0011226

Summaries for Hepatitis D

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis delta virus, which is an incomplete virus that requires the helper function of Hepatitis B virus to replicate and only occurs among people who are infected with the Hepatitis B virus. The infection has symptom fatigue, has symptom lethargy, has symptom anorexia, has symptom nausea, has symptom jaundice, has symptom clay-colored stools, has symptom dark urine, has symptom changes in personality, has symptom disturbances in sleep, has symptom confusion, has symptom abnormal behavior, has symptom somnolence, and has symptom coma.

MalaCards based summary : Hepatitis D, also known as hepatitis delta, is related to hepatitis and hepatitis b, and has symptoms including fatigue, lethargy and anorexia. An important gene associated with Hepatitis D is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Imipramine/Desipramine Pathway, Pharmacokinetics and Gefitinib Pathway, Pharmacokinetics. The drugs Peginterferon alfa-2b and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include liver, liver and testes.

Wikipedia : 76 Hepatitis D (hepatitis delta) is a disease caused by the hepatitis D virus (HDV), a small spherical... more...

Related Diseases for Hepatitis D

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis D via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Related Disease Score Top Affiliating Genes
1 hepatitis 31.0 F2 GPT IFNA2
2 hepatitis b 30.7 F2 GPT IFNA2
3 hepatitis e 29.1 CD40LG F2 GPT
4 viral hepatitis 28.8 CD40LG F2 GPT IFNA2
5 hepatitis a 28.5 CD40LG F2 GPT IFNA2
6 porphyria, acute hepatic 11.0
7 cryoglobulinemia, familial mixed 10.5 CD40LG IFNA2
8 spinocerebellar ataxia, autosomal recessive 10 10.5 CD40LG IFNA2
9 scrub typhus 10.5 CD40LG GPT
10 phlebotomus fever 10.5 CD40LG IFNA2
11 epidemic typhus 10.5 CD40LG GPT
12 hepatoportal sclerosis 10.4 F2 GPT
13 granulomatous hepatitis 10.4 CD40LG IFNA2
14 kwashiorkor 10.4 F2 GPT
15 hepatic tuberculosis 10.4 F2 GPT
16 hepatic coma 10.4 F2 GPT
17 hemangioma of liver 10.4 F2 IFNA2
18 giant hemangioma 10.4 F2 IFNA2
19 nonalcoholic steatohepatitis 10.4 F2 GPT
20 choledocholithiasis 10.4 F2 GPT
21 fournier gangrene 10.4 CD40LG F2
22 livedoid vasculopathy 10.4 CD40LG F2
23 analbuminemia 10.3 F2 GPT
24 hantavirus pulmonary syndrome 10.3 CD40LG F2
25 acute liver failure 10.3 F2 GPT
26 splenic disease 10.3 CD40LG F2
27 bile duct disease 10.3 F2 GPT
28 korean hemorrhagic fever 10.3 CD40LG F2
29 branch retinal artery occlusion 10.3 CD40LG F2
30 endocardium disease 10.3 CD40LG F2
31 serotonin syndrome 10.3 CYP2D6 IFNA2
32 cholecystitis 10.2 F2 GPT
33 autoimmune disease of gastrointestinal tract 10.2 CD40LG CYP2D6
34 obstructive jaundice 10.2 F2 GPT
35 hepatic encephalopathy 10.2 F2 GPT
36 blood coagulation disease 10.2 CD40LG F2
37 alcoholic hepatitis 10.2 F2 GPT
38 leptospirosis 10.2 CD40LG F2
39 dengue hemorrhagic fever 10.2 CD40LG F2
40 viral infectious disease 10.1 CD40LG GPT IFNA2
41 hemorrhagic disease 10.1 CD40LG F2
42 antiphospholipid syndrome 10.1 CD40LG F2
43 multiple chemical sensitivity 10.1 CYP2C9 CYP2D6
44 sickle cell anemia 10.0 CD40LG F2
45 portal hypertension 10.0 F2 GPT
46 blood platelet disease 10.0 CD40LG F2
47 liver disease 10.0
48 hemorrhagic fever 10.0 CD40LG F2 GPT
49 hepatocellular carcinoma 10.0
50 hepatitis c 10.0

Graphical network of the top 20 diseases related to Hepatitis D:



Diseases related to Hepatitis D

Symptoms & Phenotypes for Hepatitis D

Symptoms:

12 (show all 13)
  • fatigue
  • lethargy
  • anorexia
  • nausea
  • jaundice
  • clay-colored stools
  • dark urine
  • changes in personality
  • disturbances in sleep
  • confusion
  • abnormal behavior
  • somnolence
  • coma

Drugs & Therapeutics for Hepatitis D

Drugs for Hepatitis D (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2b Approved Phase 4,Phase 3 99210-65-8, 215647-85-1
2
Ribavirin Approved Phase 4,Phase 2,Phase 1 36791-04-5 37542
3
Everolimus Approved Phase 4 159351-69-6 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
6
Mycophenolic acid Approved Phase 4 24280-93-1 446541
7
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
8
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
9 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Antimetabolites Phase 4,Phase 2,Phase 1
11 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1
13 interferons Phase 4,Phase 3,Phase 2,Phase 1
14 Vaccines Phase 4
15 Anti-Bacterial Agents Phase 4
16 Antibiotics, Antitubercular Phase 4
17 Antifungal Agents Phase 4
18 Antitubercular Agents Phase 4
19 Immunosuppressive Agents Phase 4
20 Liver Extracts Phase 4,Phase 2
21
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
22 Anti-HIV Agents Phase 3,Phase 2,Phase 1
23 Anti-Retroviral Agents Phase 3,Phase 2,Phase 1
24 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
25 Reverse Transcriptase Inhibitors Phase 3,Phase 2
26
Tenofovir Phase 3,Phase 2 147127-20-6 464205
27
Ritonavir Approved, Investigational Phase 2,Phase 1 155213-67-5 392622
28
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
29
Ezetimibe Approved Phase 2 163222-33-1 150311
30
Coal tar Approved Phase 2 8007-45-2
31
Entecavir Approved, Investigational Phase 2 142217-69-4 153941
32 Cytochrome P-450 CYP3A Inhibitors Phase 2,Phase 1
33 Cytochrome P-450 Enzyme Inhibitors Phase 2,Phase 1
34 HIV Protease Inhibitors Phase 2,Phase 1
35
protease inhibitors Phase 2,Phase 1
36 Adjuvants, Immunologic Phase 2
37 Anticholesteremic Agents Phase 2
38 Hypolipidemic Agents Phase 2
39 Lipid Regulating Agents Phase 2
40
Tipranavir Approved, Investigational Phase 1 174484-41-4 65027
41 Iron-Dextran Complex Phase 1
42 Antibodies
43 Immunoglobulins

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
2 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
3 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
4 A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD) Completed NCT02732639 Phase 3 Pegylated Interferon (PEG-IFN) alfa-2a
5 A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D. Completed NCT01088659 Phase 3 peginterferon alfa-2a [Pegasys];placebo;tenofovir
6 Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603) Completed NCT00686790 Phase 3
7 A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D Completed NCT03546621 Phase 2 Myrcludex B;Myrcludex-B;Myrcludex-B;Tenofovir
8 Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir Completed NCT02511431 Phase 2 Lonafarnib;Ritonavir
9 Lonafarnib for Chronic Hepatitis D Completed NCT01495585 Phase 2 Lonafarnib
10 A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD) Completed NCT02731131 Phase 2 Peginterferon alfa-2a;Ribavirin
11 Pegylated Interferon to Treat Chronic Hepatitis D Completed NCT00023322 Phase 2 Peginterferon Alpha-2a
12 HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis Completed NCT00932971 Phase 2 PEG-IFN alfa-2a, Tenofovir;PEG-IFN alfa-2a, placebo
13 REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection Completed NCT02233075 Phase 2 REP 2139-Ca + Pegasys (TM)
14 Lonafarnib With and Without Ritonavir in HDV (LOWR-1) Completed NCT02430181 Phase 2 lonafarnib;PEG IFN-a;Ritonavir
15 Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection Completed NCT02637999 Phase 1, Phase 2 PEG IFN alfa-2a;Myrcludex B
16 Lonafarnib With Ritonavir in HDV (LOWR-2) Completed NCT02430194 Phase 2 lonafarnib;Ritonavir;PEG IFN-a
17 Titrating-Dose of Lonafarnib in Combination With Ritonavir Completed NCT02527707 Phase 2 lonafarnib;Ritonavir
18 Lamivudine for Chronic Hepatitis B Completed NCT00001457 Phase 2 Lamivudine
19 Ezetimibe for Patients With Chronic Hepatitis D Recruiting NCT03099278 Phase 2 Ezetimibe
20 Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D Active, not recruiting NCT03105310 Phase 2 Pegylated interferon alfa;Ezetimibe
21 A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection Active, not recruiting NCT02765802 Phase 2 Lambda
22 A Study of Lonafarnib With or Without Ritonavir in Patients With HDV Not yet recruiting NCT02968641 Phase 2 Lonafarnib;Ritonavir
23 Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic HBV Terminated NCT02577029 Phase 2 ARC-520;Entecavir;Tenofovir disoproxil
24 Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic I Completed NCT02259855 Phase 1 Tipranavir;Ritonavir;Pegylated interferon;Ribavirin
25 Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV) Terminated NCT01316185 Phase 1 EBP921
26 Mother-to-child Hepatitis D Transmission Completed NCT02044055
27 Hepatitis Delta Infections in Hemophiliacs Completed NCT00005305
28 Delta Hepatitis and Liver Disease in Hemophiliacs Completed NCT00005304
29 The Hepatitis Delta International Network Recruiting NCT02375906
30 Liver Fibrosis in Zambian HIV-HBV Co-infected Patients Recruiting NCT02344680 Anti-HIV Agents
31 Evaluation of Patients With Liver Disease Recruiting NCT00001971
32 Chronic Hepatitis B Virus Infection in Zambia Recruiting NCT03158818
33 A Long Term Follow-up Study of Patients From the REP 301 Protocol Active, not recruiting NCT02876419
34 Epidemiology of Hepatitis B, C and Delta in Reunion Island Not yet recruiting NCT03362866
35 An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a) Terminated NCT01861444

Search NIH Clinical Center for Hepatitis D

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hepatitis d

Genetic Tests for Hepatitis D

Anatomical Context for Hepatitis D

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis D:

19
Liver

MalaCards organs/tissues related to Hepatitis D:

41
Liver, Testes, B Cells, T Cells

Publications for Hepatitis D

Articles related to Hepatitis D:

(show top 50) (show all 389)
# Title Authors Year
1
Prevalence of Hepatitis B virus and Hepatitis D virus coinfection in Western Burkina Faso and molecular characterization of the detected virus strains. ( 29432880 )
2018
2
Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. ( 29775812 )
2018
3
Epidemiology and patient characteristics of hepatitis D virus infection in the West of Scotland 2011-2016. ( 29851188 )
2018
4
Hepatitis D Viremia Among Injection Drug Users in San Francisco. ( 29800369 )
2018
5
Hepatitis D virus infection in Kermanshah, west of Iran: seroprevalence and viremic infections. ( 29910856 )
2018
6
Are immunoglobulins against the HBsAg still needed in liver transplantation for hepatitis D? ( 29356031 )
2018
7
Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults. ( 29698488 )
2018
8
Epidemiological data for hepatitis D in Africa. ( 29241610 )
2018
9
Molecular Signature and Mechanisms of Hepatitis D Virus-Associated Hepatocellular Carcinoma. ( 29858376 )
2018
10
A new dual-targeting real-time RT-PCR assay for hepatitis D virus RNA detection. ( 29941366 )
2018
11
Epidemiological data for hepatitis D in Africa - Authors' reply. ( 29241612 )
2018
12
Epidemiology and phylogenetic analysis of hepatitis D virus infection in Australia. ( 29761607 )
2018
13
Epidemiological data for hepatitis D in Africa. ( 29241611 )
2018
14
Clinical and laboratory characteristics of hepatitis d in Republic of Sakha (Yakutia). ( 29602929 )
2018
15
A comprehensive bioinformatic analysis of hepatitis D virus (HDV) full-length genomes. ( 29406571 )
2018
16
Hepatitis D diagnostics:Utilization and testing in the United States. ( 29596839 )
2018
17
Hepatitis D infection in Brazil: Prevalence and geographical distribution of anti-Delta antibody. ( 29663457 )
2018
18
Hepatitis D virus replication is sensed by MDA5 and induces IFN-I^/I> responses in hepatocytes. ( 29524530 )
2018
19
Targeting Hepatitis D. ( 29471567 )
2018
20
Tat-enhanced delivery of the C terminus of HDAg-L inhibits assembly and secretion of hepatitis D virus. ( 29247673 )
2018
21
Hepatitis D infection should be taken in mind while evaluating neonatal outcomes related to maternal hepatitis B infection. ( 28854842 )
2017
22
Nucleic acid polymers: much-needed hope for hepatitis D? ( 28964702 )
2017
23
Potential effect of lamivudine-induced S gene mutations on liver-related pathogenesis in hepatitis D virus infection. ( 28103643 )
2017
24
Prevalence and risk factors of hepatitis D virus infection in patients with chronic hepatitis B infection attending the three main tertiary hospitals in Libya. ( 29241726 )
2017
25
Investigational drugs in development for Hepatitis D. ( 28730878 )
2017
26
A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. ( 28223128 )
2017
27
Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D. ( 28043091 )
2017
28
The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. ( 27803174 )
2017
29
Drug-drug interaction potential of the hepatitis B and hepatitis D virus entry inhibitor myrcludex B assessed in vitro. ( 29134945 )
2017
30
Hepatitis D virus in Africa: several unmet needs. ( 28911754 )
2017
31
Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D - authors' reply. ( 28043094 )
2017
32
Hepatitis D, B and C virus (HDV/HBV/HCV) coinfection as a diagnostic problem and therapeutic challenge. ( 28856286 )
2017
33
Sequencing of the Hepatitis D Virus RNA WHO International Standard. ( 28359844 )
2017
34
Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. ( 28911765 )
2017
35
Prevalence and epidemiology of hepatitis D among patients with chronic hepatitis B virus infection: a report from Northern Spain. ( 27902514 )
2017
36
Hepatitis D ( 29261923 )
2017
37
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. ( 28964701 )
2017
38
Transmission of hepatitis D virus between spouses: A longitudinal study of the first reported Canadian case. ( 28331807 )
2017
39
A novel toolbox for the in vitro assay of hepatitis D virus infection. ( 28079152 )
2017
40
Elevated serum I^2-microglobulin in individuals coinfected with hepatitis B and hepatitis D virus in a rural settings in Southwest Nigeria. ( 29221492 )
2017
41
Prevalence and molecular characterization of hepatitis D virus in Saudi Arabia: A single-center study. ( 28611341 )
2017
42
Hepatitis B Virus-Hepatitis D Virus mother-to-child co-transmission: A retrospective study in a developed country. ( 28834623 )
2017
43
Serum cholinesterase: A predictive biomarker of hepatic reserves in chronic hepatitis D. ( 28839517 )
2017
44
Recent advances in managing hepatitis D. ( 28928961 )
2017
45
Prevalence of Hepatitis D Among Patients with Hepatitis B Viral Infection Attending a Tertiary Care Centre of Nepal. ( 29453472 )
2017
46
Performance Characteristics of a New Consensus Commercial Kit for Hepatitis D Virus RNA Viral Load quantification. ( 27881614 )
2016
47
High prevalence of chronic hepatitis D virus infection in Eastern Turkey: urbanization of the disease. ( 27186189 )
2016
48
A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa. ( 27821080 )
2016
49
Modification of Three Amino Acids in Sodium Taurocholate Cotransporting Polypeptide Renders Mice Susceptible to Infection with Hepatitis D Virus In Vivo. ( 27466423 )
2016
50
Polymorphisms in the IL28B gene (rs12979860, rs8099917) and the virological response to pegylated interferon therapy in hepatitis D virus patients. ( 27382939 )
2016

Variations for Hepatitis D

Expression for Hepatitis D

Search GEO for disease gene expression data for Hepatitis D.

Pathways for Hepatitis D

Pathways related to Hepatitis D according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.3 CYP2C9 CYP2D6
2
Show member pathways
11.16 CYP2C9 CYP2D6
3
Show member pathways
11.11 CYP2C9 CYP2D6
4
Show member pathways
11 CYP2C9 CYP2D6
5 10.86 CYP2C9 F2
6 10.58 IFNA2 IFNL3
7
Show member pathways
9.98 IFNA2 IFNL3

GO Terms for Hepatitis D

Cellular components related to Hepatitis D according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.02 CD40LG F2 GPT IFNA2 IFNL3

Biological processes related to Hepatitis D according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.56 CD40LG F2 IFNA2 IFNL3
2 B cell differentiation GO:0030183 9.46 CD40LG IFNA2
3 B cell proliferation GO:0042100 9.43 CD40LG IFNA2
4 drug metabolic process GO:0017144 9.4 CYP2C9 CYP2D6
5 exogenous drug catabolic process GO:0042738 9.37 CYP2C9 CYP2D6
6 organic acid metabolic process GO:0006082 9.32 CYP2C9 CYP2D6
7 oxidative demethylation GO:0070989 9.16 CYP2C9 CYP2D6
8 drug catabolic process GO:0042737 8.96 CYP2C9 CYP2D6
9 monoterpenoid metabolic process GO:0016098 8.62 CYP2C9 CYP2D6

Molecular functions related to Hepatitis D according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.4 CYP2C9 CYP2D6
2 drug binding GO:0008144 9.37 CYP2C9 CYP2D6
3 monooxygenase activity GO:0004497 9.32 CYP2C9 CYP2D6
4 oxygen binding GO:0019825 9.26 CYP2C9 CYP2D6
5 steroid hydroxylase activity GO:0008395 9.16 CYP2C9 CYP2D6
6 cytokine activity GO:0005125 9.13 CD40LG IFNA2 IFNL3
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 8.62 CYP2C9 CYP2D6

Sources for Hepatitis D

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....